Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-31

So a lot of negatives as expected as the extra patient numbers not indicated in that announcement. Pity yes but I did read through the rest and saw extras that are new to date. They now have indication of extended shelf life of there nano product, this is very important for customers who purchase. Also now told
side effects from use of gadolinium on certain patients prevents its use and iron oxide nano particles are the perfect replacement and it’s looking good, we will have another imaging area added to the mix in the elusive brain cancer scan. Add these income earners to those we already know of and the business model to earn income still looks good. It’s a pity they did not give priority to the MRI path first as those many machines are already out there and proving up a new imaging agent for it would be a lot quicker and revenues would roll in. The breast cancer is going to be a long wait with second trials needed when they finally complete this one then they have to get the actual machine approved and in production and distribution. We need revenue pure and simple.